SEC Form 4 · accession 0001553350-17-000461
HEAT BIOLOGICS, INC. · HTBX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John J Monahan
Director
Period of report
Apr 28, 2017
Accepted (ET)
May 2, 2017 · 12:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001476963
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Apr 28, 2017 | A | 3,958 | — | A | 5,169 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On March 7, 2017, Heat Biologics, Inc. (the "Company") entered into a Stock Purchase Agreement, as amended, with Pelican Therapeutics, Inc. ("Pelican"), and certain holders of the outstanding capital stock of Pelican, including the reporting person, who agreed to sell their shares in Pelican to the Company (the "Acquisition"). The reporting person is a member of the Company's board of directors.
- F2(Continued from footnote (1)) In connection with the closing of the Acquisition, which occurred on April 28, 2017, the reporting person sold approximately 85% of his shares of capital stock in Pelican held through a limited liability company in exchange for cash consideration and 3,958 shares of the Company's common stock, $0.0002 par value per share (the "Common Stock"). All of the shares of Common Stock issued in the Acquisition are currently held in escrow and are subject to forfeiture during the six month period following the Acquisition to satisfy certain indemnification obligations.